
Steffen Ormanns

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2756241/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The impact of adjuvant therapy on outcome in <scp>UICC</scp> stage I pancreatic cancer. International Journal of Cancer, 2022, , .	2.3	4
2	Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer. JNCI Cancer Spectrum, 2022, 6, .	1.4	7
3	Impact of previous transurethral prostate surgery on health-related quality of life after radical prostatectomy: Does the interval between surgeries matter?. World Journal of Urology, 2021, 39, 1431-1438.	1.2	3
4	Radical cystectomy for locally advanced urothelial carcinoma of the urinary bladder: Health-related quality of life, oncological outcomes and predictors for survival. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 299.e15-299.e21.	0.8	3
5	NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU. Archives of Gynecology and Obstetrics, 2021, 303, 1331-1345.	0.8	11
6	Histomorphology and Immunohistochemistry of a Congenital Nephromegaly Demonstrate Concurrent Features of Heritable and Acquired Cystic Nephropathies in a Girgentana Goat (Capra falconeri). Case Reports in Veterinary Medicine, 2021, 2021, 1-8.	0.2	0
7	Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 1666-1678.	1.3	6
8	Primary Chemotherapy in a 47-Year-Old Patient with Giant Ulcerative and Necrotizing Nonseminomatous Testicular Germ Cell Tumor. Case Reports in Oncology, 2021, 14, 681-689.	0.3	1
9	T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nature Biomedical Engineering, 2021, 5, 1246-1260.	11.6	80
10	Rituximab Treatment of Hairy Cell Leukemia in a Patient with <i>Mycobacterium kansasii</i> Infection: A Case Report. Oncology Research and Treatment, 2021, 44, 1-4.	0.8	0
11	Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox. Journal of Cancer Research and Clinical Oncology, 2020, 146, 391-399.	1.2	13
12	Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. JNCI Cancer Spectrum, 2020, 4, pkz060.	1.4	7
13	Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study. British Journal of Cancer, 2020, 123, 1370-1376.	2.9	10
14	Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model. Cancer Immunology, Immunotherapy, 2020, 69, 2101-2112.	2.0	12
15	Protein Kinase D1, Reduced in Human Pancreatic Tumors, Increases Secretion of Small Extracellular Vesicles From Cancer Cells That Promote Metastasis to Lung in Mice. Gastroenterology, 2020, 159, 1019-1035.e22.	0.6	47
16	Advances in cancer immunotherapy 2019 – latest trends. Journal of Experimental and Clinical Cancer Research, 2019, 38, 268.	3.5	401
17	Pro-Angiogenic Macrophage Phenotype to Promote Myocardial Repair. Journal of the American College of Cardiology, 2019, 73, 2990-3002.	1.2	117
18	Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer. Cancers, 2019, 11, 39.	1.7	84

STEFFEN ORMANNS

#	Article	IF	CITATIONS
19	Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2018, 155, 1625-1639.e2.	0.6	152
20	POLE gene hotspot mutations in advanced pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2161-2166.	1.2	15
21	Loss of desmoglein 2 promotes tumorigenic behavior in pancreatic cancer cells. Molecular Carcinogenesis, 2017, 56, 1884-1895.	1.3	38
22	Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. British Journal of Cancer, 2017, 116, 1462-1469.	2.9	25
23	Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncolmmunology, 2017, 6, e1310358.	2.1	111
24	Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research. BMC Cancer, 2017, 17, 374.	1.1	1
25	Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer – A retrospective cohort study. Thrombosis Research, 2017, 157, 9-15.	0.8	49
26	The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy. International Journal of Molecular Sciences, 2017, 18, 1094.	1.8	20
27	Development of a reliable and accurate algorithm to quantify the tumor immune stroma (QTiS) across tumor types. Oncotarget, 2017, 8, 114935-114944.	0.8	21
28	Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Pancreatology, 2016, 16, 593-598.	0.5	58
29	Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells. OncoImmunology, 2016, 5, e1175794.	2.1	70
30	Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2585-2591.	1.2	26
31	Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials. British Journal of Cancer, 2016, 115, 1520-1529.	2.9	20
32	C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer. OncoImmunology, 2016, 5, e1105428.	2.1	58
33	Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. Cancer Letters, 2016, 381, 259-268.	3.2	30
34	Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma. British Journal of Cancer, 2015, 113, 1460-1466.	2.9	25
35	Impact of SPARC expression level on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: A pooled analysis from prospective clinical and translational trials Journal of Clinical Oncology, 2015, 33, e15264-e15264.	0.8	1
36	ALK expression is absent in pancreatic ductal adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1625-1628.	1.2	5

STEFFEN ORMANNS

#	Article	IF	CITATIONS
37	Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. European Journal of Cancer, 2014, 50, 1891-1899.	1.3	31
38	Epithelial-Mesenchymal Transition Induces Endoplasmic-Reticulum-Stress Response in Human Colorectal Tumor Cells. PLoS ONE, 2014, 9, e87386.	1.1	21
39	WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear β-Catenin depend on active PI3K signaling. Oncotarget, 2014, 5, 2999-3011.	0.8	51
40	Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts. World Journal of Gastroenterology, 2014, 20, 10769.	1.4	20
41	KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. Journal of Gastroenterology, 2013, 48, 544-548.	2.3	66
42	Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104) Journal of Clinical Oncology, 2013, 31, 189-189.	0.8	0